Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
9.02M
-
Shares change
-
+2.75M
-
Total reported value, excl. options
-
$83M
-
Value change
-
+$29.1M
-
Number of buys
-
21
-
Number of sells
-
-14
-
Price
-
$9.20
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2018
46 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q2 2018.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.02M shares
of 77.3M outstanding shares and own 11.66% of the company stock.
Largest 10 shareholders include Capital World Investors (1.43M shares), venBio Select Advisor LLC (1.2M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (800K shares), BVF INC/IL (721K shares), ORBIMED ADVISORS LLC (635K shares), RENAISSANCE TECHNOLOGIES LLC (490K shares), Granite Point Capital Management, L.P. (482K shares), Schonfeld Strategic Advisors LLC (455K shares), ACUTA CAPITAL PARTNERS, LLC (450K shares), and SPHERA FUNDS MANAGEMENT LTD. (439K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.